Plain-English translation of NCT07901387 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is testing whether certain biomarkers—measurable substances found in blood and urine—can better diagnose and track extrapulmonary tuberculosis (TB that develops outside the lungs). Researchers are looking for more reliable ways to identify this form of TB because current tests often miss it, especially in areas with limited medical resources. The study will compare these new biomarkers against traditional diagnostic methods to see if they work better.
Extrapulmonary TB is difficult to diagnose with standard tests, which means many patients go undiagnosed or receive treatment too late. In Kenya and other high-burden regions, this delayed diagnosis leads to serious illness and death. This study aims to fill that gap by developing faster, more accurate diagnostic methods that can work in settings with limited laboratory equipment.
You likely qualify if…
You likely don't qualify if…
You will visit one of two hospitals in Nairobi where researchers will collect your medical history and demographic information. You will provide blood, urine, and sputum samples, and depending on your suspected TB type, samples may be collected from affected areas such as lymph nodes or other sites. The study will follow you over time—from November 2024 through October 2028—to track how well the new biomarkers work for diagnosis and to monitor your response to treatment if you receive TB therapy.
AI-generated summary from trial data · Nov 2, 2026 · Not medical advice
Kenya